loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Global Health Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Global Health Ltd. 07 Nov 2025 18:04 PM
Result PDF

Q2FY26 Quarterly Result Announced for Global Health Ltd.

Healthcare Facilities company Global Health announced Q2FY26 results

  • Consolidated Total Income of Rs 11,189 million, compared to Rs 9,748 million in Q2FY25; reflecting a growth of 14.8 % YoY.
  • EBITDA1 (ex-Noida3 ) grew 13.7 % YoY to Rs 2,804 with margins of 25.2% compared to 25.3% in Q2FY25. Including Noida, EBITDA was Rs 2,607 million, up 5.7% YoY, with margins at 23.3%.
  • Medanta Noida commenced operations in September 2025. The hospital generated Revenue of Rs 39 million and EBITDA loss of Rs 197 million.
  • Profit After Tax was Rs 1,584 million, growth of 21.1% YoY. PAT margins improved to 14.2% from 13.4% in Q2FY25.
  • During the quarter, 37 new beds were added at Patna, taking total bed addition to 57 beds in H1FY26 in Patna.
  • Occupied bed days increased by 7.7% YoY, representing an occupancy of ~64% on increased bed capacity.
  • ARPOB grew by 5.5% YoY to Rs 65,570 in Q2FY26, driven by increase in realization and change in speciality mix.
  • Volume growth remained robust, In-patient count increased by 12.7% and Out-patient count increased by 14.9% YoY.
  • Matured hospitals revenue was Rs 7,200 million, growth of 5.4% YoY. EBITDA was Rs 1,696 million, growth of 0.4% YoY.
  • Developing hospitals ex Noida, Revenue was Rs 3,531 million, growth of 28.3% YoY. EBITDA increased 34.0% YoY to Rs 1,112 million, with margins improving to 31.5% compared to 30.1% in Q2FY25. Including Noida, EBITDA stood at Rs 915 million, with margin of 25.6%, reflecting the impact of initial ramp-up costs.
  • International Patients Revenue increased by 48.5% YoY to Rs 762 million in Q2FY26, driven by increased international patient volume.
  • OPD Pharmacy (Hospital & Retail) continues to register strong double digit growth. Revenue increased by 23.9% YoY to Rs 456 million in Q2FY26.

Pankaj Sahni, Group CEO & Director, said: “We are extremely pleased to share that in September 2025, we launched our sixth hospital, a stateof-the-art, 550-bed facility in Noida. Over 150 doctors across key specialties have already joined the hospital, supported by the deployment of advanced medical technologies, they will be able to deliver world-class care in the region. We are encouraged by the initial response from the community and are progressively ramping up operations.

During the quarter, the Company delivered a strong performance, with Revenue Growth of 15% year-on-year and 6% sequential growth. EBITDA (excluding Noida) grew 14% year-on-year and 10% sequentially. Growth momentum remained broad-based across our network."

Result PDF

Result PDF

Healthcare Facilities company Global Health announced Q1FY26 results

  • Consolidated Total Income of Rs 10,513 million, grew by 19.1% YoY.
  • EBITDA was Rs 2,553 million, growth of 22.6% YoY.
  • EBITDA margins improved to 24.3% compared to 23.6% in Q1FY25.
  • Profit After Tax was Rs 1,590 million, with improved PAT margins of 15.1%.
  • Occupied bed days increased by 13.3%, representing an occupancy of 63.2% on increased bed capacity.
  • ARPOB grew by 4.0% to Rs 66,584 in Q1FY26 driven by increase in realization in Gurugram unit and change in speciality mix.
  • In-patients count increased by 14.2% and Out-patients count increased by 13.1% YoY.
  • Matured hospitals revenue was Rs 7,006 million, growth of 10.7% on YoY basis. EBITDA was Rs 1,640 million, growth of 6.7% YoY.
  • Developing hospitals revenue was Rs 3,219 million, growth of 35.9% on YoY basis. EBITDA was Rs 942 million, strong growth of 59.8% YoY.
  • During the period, International Patients Revenue increased by 33.8% YoY to Rs 636 million, driven by increased international patient volume.
  • OPD Pharmacy (Hospital & Retail) continues to register strong double digit growth. Revenue increased by 21.6% YoY to Rs 404 million.

Pankaj Sahni, Group CEO & Director said: “I am pleased to report another strong quarter, delivering our highest ever Total Income and EBITDA with YoY growth of 19% and 23% respectively. This robust performance was driven by increased patient volumes and improved realizations, with consistent growth across mature hospitals as well as Lucknow and Patna hospital.

We successfully operationalized our 110-bed hospital in Ranchi in July 2025 and remain on track to commission our upcoming 550-bed facility in Noida in Q2FY26. Backed by a balanced portfolio of assets and a strong balance sheet, we are well-positioned to execute our long-term growth strategy and further expand the Medanta model of care across the region.”

Result PDF

Healthcare Facilities company Global Health announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Consolidated Total Income of Rs 9,542 million, grew by 14.1% YoY, primarily led by patient volume growth
  • EBITDA was Rs 2,476 million, growth of 19.8% YoY. EBITDA margins improved from 24.7% in Q4FY24 to 26.0% in Q4FY25
  • Profit After Tax was Rs 1,014 million with PAT margins of 10.6%
  • In Q4FY25 Profit After Tax is impacted due to non-recurring exceptional expense item of Rs 499 million arising due to merger of MHPL with GHL. Adjusted PAT was Rs 1,387 million with margins of 14.5% and growth of 8.9% YoY

FY25 Financial Highlights:

  • Consolidated Total Income of Rs 37,714 million, grew by 12.6% YoY. The growth was primarily driven by increase in patient volumes
  • EBITDA was Rs 9,562 million, growth of 9.4% YoY. EBITDA margins stood at 25.4% compared to 26.1% in FY24
  • Profit After Tax was Rs 4,813 million, with PAT margins of 12.8%
  • Profit After Tax was impacted due to non-recurring exceptional expense item of Rs 499 million arising due to merger of MHPL (Lucknow entity) with GHL. Adjusted PAT was Rs 5,186 million with margins of 13.8% and growth of 8.5% YoY
  • The board of directors have recommended a final dividend of 25% on the face value of Rs 2 per share i.e. Rs 0.50 per share

Commenting on FY2025 results, Pankaj Sahni, Group CEO and Director said: "FY2025 was a landmark year for us as we celebrated 15 years of our flagship facility in Gurugram – the foundation of our journey in delivering world-class, patient-centric care. We are deeply honoured that Medanta Gurugram, also known as “The Medicity,” has been ranked India’s Best Private Hospital by Newsweek for the sixth consecutive year. This recognition is a testament to our unwavering focus on clinical excellence and innovation.

Throughout the year, we remained steadfast in our commitment to providing the highest quality of patient care while continuing to invest in strengthening our clinical and technological capabilities across the Group.

We are excited about our upcoming 550-bed facility in Noida, which is on track to commence operations in Q2 FY2026. This is part of a broader plan to add 1,000 beds over the next two years, enhancing our capacity to serve growing patient needs.

In addition, we announced three significant greenfield projects in the high-growth markets of Mumbai, Pitampura, and Guwahati. These projects, expected to be operational in the next 3–4 years, will not only expand our footprint but also meaningfully diversify our presence across the country"

Result PDF

Healthcare Facilities company Global Health announced Q3FY25 results

  • Total income of Rs. 9,595 million, growth of 12.3% YoY.
  • EBITDA of Rs. 2,538 million, growth of 8.4% YoY with EBITDA margins at 26.5%.
  • Profit after tax of Rs. 1,429 million, growth of 15.6% YoY. PAT Margins increased to 14.9% compared to 14.5% in Q3FY24.
  • Average occupied bed days increased by 10.5% YoY, representing an occupancy of 63.6% on increased bed capacity.
  • Average revenue per occupied bed (ARPOB) marginally grew by 1.2% YoY to Rs. 61,307.
  • In-patients count increased by 12.9% and Out-patient count increased by 8.7% YoY.
  • Matured hospitals revenue was Rs. 6,466 million, growth of 10.1% on YoY basis. EBITDA was Rs. 1,617 million, growth of 9.0% on YoY basis.
  • Developing hospitals revenue was Rs 3,004 million, growth of 9.5% on YoY basis. EBITDA was Rs 1,015 million, growth of 4.8% on YoY basis.
  • Revenue from international patients increased by 14.3% to YoY to Rs. 541 million.
  • Out-patient pharmacy (Hospital Retail) continues to register strong growth. Revenue increased by 21.4% from Rs 290 million in Q3FY24 to Rs 352 million in Q3FY25.

Pankaj Sahni, Group CEO and Director said: "I am pleased to share that we have delivered a strong performance this quarter, driven by higher patient volumes and strong contributions from our developing hospitals.

Additionally, we are excited to announce our expansion into Ranchi with a new ~110-bed hospital under a long-term lease agreement. Strategically located just 1.2 km from our existing Medanta Ranchi hospital, the new facility enables seamless integration and operational synergies. This expansion will further strengthen our capacity to meet the growing healthcare needs in the region while raising the standard of healthcare delivery.”

Result PDF

Healthcare Facilities company Global Health announced Q2FY25 results

Financial Highlights:

  • Total income of Rs 9,748 million, growth of 12.7% YoY and 10.4% QoQ.
  • EBITDA was Rs 2,465 million, growth of 5.5% YoY and 18.4% QoQ. EBITDA margins were at 25.3% in Q2FY25.
  • Profit after tax was Rs 1,308 million, growth of 4.5% YoY and 23.1% QoQ. PAT margins were 13.4% compared to 14.5% in Q2FY24.
  • Net cash surplus of Rs 7,186 million at the end of 30th September, 2024.
  • During the quarter, 52 bed were added at Lucknow and 66 beds at Patna resulting in total bed addition of 118 beds in Q2FY25.
  • Average occupied bed days increased by 9.1% YoY, with strong occupancy of 64.3% on increased bed capacity.
  • In-patients count increased by 8.8% YoY; Out-patients count increased by 6.6% YoY.
  • ARPOB marginally grew by 1.9% YoY to Rs 62,140 in Q2FY25 due to combination of tariff increase in Matured facility and change in case mix across the group.
  • Matured hospitals revenue was Rs 6,882 million, strong growth of 13.5% YoY and 7.8% on QoQ basis. EBITDA was Rs 1,739 million, growth of 12.5% YoY and 9.4% on QoQ basis.
  • Developing hospitals revenue was Rs 2,754 million, growth of 4.2% YoY and 16.2% on QoQ basis. EBITDA was Rs 823 million, down by 8.2% YoY and strong growth of 41.7% on QoQ basis.
  • During the quarter, International Patients Revenue was Rs 513 million.
  • Out-patient pharmacy (Hospital Retail) continues to register strong growth. Revenue increased by 24.5% from Rs 298 million in Q2FY24 to Rs 371 million in Q2FY25.

Other Highlights:

  • During the quarter, 52 bed were added at Lucknow and 66 beds at Patna resulting in total bed addition of 118 beds.
  • 25 doctors on-boarded across facilities to further strengthen clinical capability.
  • New Da Vinci Xi robot introduced in Lucknow and additional Da Vinci Xi robot operationalized in Gurugram.
  • Medanta Gurugram performed its first CAR-T Cell therapy, an advanced cancer treatment that harnesses the power of the patient’s own immune system to fight cancer.
  • Medanta Gurugram achieves significant milestone of completing 3,000 kidney transplants.
  • Medanta Lucknow completes 100 breast cancer surgeries.
  • Medanta Gurugram doctors successfully performed bilateral lung transplant in a patient with ILD and complex autoimmune condition.
  • Medanta Gurugram doctors uses minimally invasive unique approach to treat rare heart condition idiopathic chylopericardium.
  • Complex and severe genetic disorder Wiskott Aldrich Syndrome cured at Medanta Gurugram using half-match stem cell transplant.

Pankaj Sahni, Group CEO and Director, said: “We are pleased to report a strong performance this quarter, achieving our highest-ever quarterly Revenue and EBITDA. Growth momentum was robust across our network hospitals, as we continue to invest in cutting-edge technologies, enhance clinical capabilities through the on-boarding of senior clinicians, and expand our network by adding more beds.

I am also excited to announce that Medanta has recently signed an Operations and Management agreement to operate and manage a state-of-the-art, 750-bed super-specialty hospital in Pitampura, New Delhi. The hospital will be jointly built by Medanta and our partners Dr. Narayan Dutt Shirmali Foundation International Charitable Trust Society. This expansion reinforces our vision of creating a high-quality healthcare delivery platform, strengthens our presence in Delhi/NCR, and underscores our commitment to elevating patient care in the region through world-class services and infrastructure.”

Result PDF

Healthcare Facilities company Global Health announced consolidated Q4FY24 & FY24 results:

FY24 Financial Highlights:

  • Total income of Rs 33,498 million, growth of 21% YoY
  • EBITDA of Rs 8,737 million compared to Rs 6,771 million, growth of 29% YoY
  • EBITDA margins improved by 154 bps to 26.1%
  • Profit after tax of Rs 4,781 million, growth of 47% YoY
  • Net cash surplus of Rs 7,720 million
  • Average occupied bed days increased by 14% YoY, representing an occupancy of 62% on increased bed capacity
  • In-patients count increased by 15%; Out-patient count increased by 18% in FY24
  • ARPOB grew by 4.7% to Rs 61,890
  • Developing hospitals revenue share of consolidated revenue increased from 27% in FY23 to 30% in FY24 amounting to Rs 9,948 million. Developing hospital EBITDA share of consolidated EBITDA increased from 32% in FY23 to 37% in FY24 amounting to Rs 3,208 million
  • During the period, International Patients Revenue increased by 24% to Rs 1,935 million, driven by increased volume in international patient admissions and higher realizations
  • In house OPD Pharmacy business continues to register strong growth. Revenue increased by 32% from Rs 850 million in FY23 to Rs 1,121 million in FY24

Q4FY24 Financial Highlights:

  • Total income of Rs 8,361 million; growth of 14% YoY
  • EBITDA of Rs 2,068 million; growth of 8% YoY
  • EBITDA margins remained stable at 24.7%
  • Profit after tax of Rs 1,273 million; growth of 26% YoY
  • Average occupied bed days increased by 9% YoY, representing an occupancy of 59% on increased bed capacity
  • ARPOB grew by 4% to Rs 63,063; In-patient count increased by 10% YoY; Out-patient count increased by 11% YoY

Commenting on FY2024 results, Pankaj Sahni, Group CEO and Director said: “I am pleased to inform that keeping with our consistent focus on quality care, Medanta has been recognized by Newsweek as India's 'Best Private Hospital' for the fifth consecutive year. Medanta Gurugram is also the only Indian private hospital to feature in the top 200 hospitals in the world.

The continued focus on providing our patients with the highest quality of care has enabled Medanta to deliver strong financial results during the year. We remain dedicated to executing our core strategy and delivering on our upcoming projects. Medanta is well-positioned to drive near-term growth with calibrated bed capacity expansions at existing hospitals and new facilities.”

Result PDF

Healthcare Facilities company Global Health announced Q3FY24 results:

Financial Performance:

  • Total Income: The consolidated total income for Global Health increased by 21% YoY to Rs 8,545 million in Q3FY24.
  • EBITDA: The company's EBITDA saw a substantial rise of 36% YoY, reaching Rs 2,340 million, with EBITDA margins expanding significantly by 305 basis points to 27.4%.
  • Net Profit: Net profit experienced remarkable growth, up by 53% YoY to Rs 1,235 million, while the PAT margins improved from 11.4% to 14.5%.

Operational Highlights:

  • Bed Occupancy: The average occupied bed days increased by 15% YoY, which corresponds to an average occupancy rate of 64% for the quarter.
  • Patient Volume: The company reported a 13% YoY increase in in-patient count and a 20% YoY increase in out-patient count.
  • Average Revenue Per Occupied Bed (ARPOB): ARPOB saw a growth of 4% YoY, reaching Rs 60,571, primarily driven by higher realizations at the Gurugram unit.

Business Growth:

  • Developing Hospitals Performance: Developing hospitals witnessed revenue growth of 33%, contributing Rs 2,742 million, which amounted to 32% of the total revenue share. Their EBITDA contribution increased from 37% to 41%, summing up to Rs 968 million.
  • Matured Hospitals Performance: The matured hospitals also demonstrated strong performance, with a revenue increase of 17% and EBITDA growth of 37%, totaling Rs 5,875 million and Rs 1,484 million respectively.
  • International Patients Revenue: Revenue from international patients rose by 6% YoY to Rs 473 million, owing to increased volume and realization.
  • OPD Pharmacy Business: There was a 28% YoY increase in revenue from the OPD pharmacy business, up from Rs 224 million in Q3 FY23 to Rs 287 million in Q3 FY24.

Strategic Developments:

  • Doctor Onboarding: Medanta onboarded a total of 253 doctors across their facilities during the first nine months of FY24, with 159 in matured hospitals and 94 in developing hospitals.
  • Upcoming Hospital in Noida: Progress on the Medanta Noida hospital is well on track with the superstructure 82% complete and operations expected to start by the end of FY2025.
  • New Joint Venture: Medanta and DLF formed a special-purpose vehicle company, GHL Hospital Limited, to construct and operate a super-specialty hospital in South Delhi.

Pankaj Sahni, Group CEO, and Director, said: "I am pleased to report that Medanta has delivered strong year-on-year performance during the quarter ended December 31, 2023. In Q3FY24, both our matured and developing units delivered robust revenue growth of 17% and 33% YoY respectively. This growth was primarily driven by increased in-patient volume and improved realization. Our commitment remains unwavering in building a sustainable long-term business model and providing the highest quality care across our key markets."

Result PDF

Healthcare Facilities company Global Health announced Q2FY24 & H1FY24 results:

  • Q2FY24:
    • Total income of Rs 8,647 million; growth of 24.5% YoY
    • EBITDA of Rs 2,336 million; growth of 35.7% YoY
    • EBITDA margins improved from 24.8% in Q2FY23 to 27% in Q2FY24
    • Profit after tax was at Rs 1,252 million; up by 46.1% YoY
    • Average Occupied bed days increased by 17.8% YoY, representing an occupancy of 64.9% in Q2FY24
    • ARPOB grew by 4.8% YoY to Rs 61,003; In-patient count increased by 19.4% and Out-patient count increased by 23.2% YoY
    • Developing hospitals (Medanta Lucknow and Medanta Patna) revenue share increased from 27% in Q2FY23 to 31% in Q2FY24 amounting to Rs 2,643 million. Developing Hospital EBITDA share increased from 33% in Q2FY23 to 38% in Q2FY24 amounting to Rs 897 million
    • Matured hospitals registered a strong growth of 19.5% YoY and EBITDA growth of 32.8% YoY amounting to Rs 6,064 million and Rs 1,545 million respectively
    • Revenue from international patients increased by 20% YoY to Rs 507 million driven by increased volumes and realization
    • OPD pharmacy business continues to register strong growth. Revenue increased by 39% YoY from Rs 215 million in Q2FY23 to Rs 298 million in Q2FY24
  • H1FY24:
    • Total income of Rs 16,592 million; growth of 25.6% YoY
    • EBITDA of Rs 4,329 million; growth of 38.0% YoY
    • EBITDA margins improved from 23.7 % in H1FY23 to 26.1% in H1FY24
    • Profit after tax of Rs 2,272 million; growth of 57.3% YoY
    • Average Occupied bed days increased by 17.1% YoY, representing an occupancy of 61.5% in H1FY24
    • ARPOB grew by 5.9% YoY to Rs 62,011 in H1FY24; In-patient volume increased by 19.4% and Out-patient volume increased by 20.5% YoY in H1FY24
    • incurred Capex of Rs 1,276 million incurred during H1FY24, out of which Rs 308 million was incurred towards Noida hospital

Commenting on Q2FY24 results, Pankaj Sahni, Group CEO and Director said, “We are pleased to report that the Company continues to deliver strong year-on-year and sequential growth across key performance indicators. The growth was seen at both matured and developing units, driven by higher patient volumes, underpinned by bed growth, doctor additions, and technology advancement. During the quarter, we received NABH accreditation for Patna Hospital, this accreditation reflects our commitment to deliver the highest quality healthcare in underserved markets. Our Noida hospital construction is on track and is expected to commence operations by FY2025 the end. As we move forward, we remain committed to executing our planned strategies while maintaining the highest quality and ethics as demonstrated by our ‘Medanta Model of Care’.

 

 

Result PDF

Healthcare Facilities company Global Health announced Q1FY24 results:

  • Total income of Rs 7,945 million; growth of 26.8% YoY
  • EBITDA of Rs 1,993 million; growth of 40.7% YoY
  • EBITDA margins improved from 22.6% in Q1FY23 to 25.1% in Q1FY24
  • Profit after tax was at Rs 1,020 million; up by 73.7% YoY
  • Average Occupied bed days increased by 16.2% YoY, representing an occupancy of 58.1% in Q1FY24 on increased bed capacity.
  • ARPOB grew by 7.1% YoY to Rs 63,148; In-patient volume increased by 19.4% and Out-patient volume increased by 17.5% YoY.
  • Developing hospitals (Medanta Lucknow and Medanta Patna) revenue share increased from 23.4% in Q1FY23 to 28.9% in Q1FY24 amounting to Rs 2,297 million. EBITDA share increased from 22.6% in Q1FY23 to 31.4% in Q1FY24 amounting to Rs 720 million.
  • Revenue from international patients increased by 45% YoY to Rs 477 million driven by increased volume and realization.
  • In-house out-patient pharmacy business continues to register strong growth. Revenue increased by 43% YoY from Rs 186 million in Q1FY23 to Rs 266 million in Q1FY24.

Commenting on Q1FY24 results, Pankaj Sahni, Group CEO and Director said, “We are excited to partner with DLF to build a new 400-bed multi-super specialty hospital in South Delhi. This hospital will allow us to serve patients across the entire NCR belt by seamlessly linking our facilities in Gurgaon, Delhi, and Noida. We are also pleased to report our Q1FY24 financial performance. The Company continues to deliver strong YoY and sequential growth driven by higher patient volumes and improvement in realization.”

 

 

 

Result PDF

Healthcare Facilities company Global Health announced Q4FY23 & FY23 results:

  • Q4FY23:
    • Highest ever quarterly total income of Rs 7,318 million; growth of 37.3% YoY
    • EBITDA of Rs 1,915 million; growth of 107.9% YoY; margins improved to 26.2%
    • Profit after tax of Rs 1,011 million; growth of 477.7% YoY
    • 126 new beds added at Medanta Lucknow
    • Occupied bed days increased by 25.6% YoY, representing an occupancy of 58% on increased bed capacity
    • ARPOB grew by 7.5% to Rs 60,880; In-patient count increased by 32.4% YoY; Out-patient count increased by 25.6% YoY
  • FY23:
    • Total income of Rs 27,592 million; growth of 25.1% YoY
    • EBITDA of Rs 6,771 million; growth of 38.3% YoY
    • EBITDA margins improved from 22.2 % in FY22 to 24.5% in FY23
    • Profit after tax of Rs 3,261 million; growth of 66.2% YoY
    • Net cash surplus of Rs 4,692
    • Strong operating cash flow with robust EBITDA to cash flow conversion of 95%
    • ARPOB grew by 8.3% to 59,098; In-patient volume increased by 32.0%; Out-patient volume increased by 15.4%
    • Developing hospitals (Medanta Lucknow and Medanta Patna) revenue share increased from 18% in FY22 to 27% in FY23 amounting to Rs 7,426 million. EBITDA share increased from 16% in FY22 to 32% in FY23 amounting to Rs 2,159 million
    • Medanta Patna which commenced IPD operations in January 2022 delivered revenue of Rs 1,707 million in FY23 and achieved EBITDA break even in its first full year of operations
    • Revenue from international patients increased by 68% to Rs 1,564 million
    • Outpatient pharmacy business continues to register strong growth. Revenue increased by 58% from Rs 536 million in FY22 to Rs 850 million in FY23

Commenting on FY23 and Q4FY23 results, Pankaj Sahni, Group CEO and Director said: “We are pleased to report that we continue to deliver on our strategy of sustainable and steady growth. For the year and quarter ending March 31, 2023, we have registered significant growth and strong financial performance across all revenue and profitability metrics. Medanta Patna is the latest unit of the Group that has delivered EBITDA breakeven in its first full year of operations. We continue our planned growth in beds and infrastructure, and remain an attractive destination for leading clinical talent which is highlighted by the addition of over 150 senior clinicians in the last fiscal year across the Group. Significant accomplishments of our clinical teams have been internationally recognized by Newsweek for the fourth consecutive year with Medanta Gurugram ranking as the 'Best Private Hospital’ in India'.”

 

Result PDF

Trending News

Midhani has secured an order of Rs. 121.75 crore

Midhani has secured an order of Rs. 121.75 crore

Published on 19-Dec-2025 09:02

Aeroflex Industries Board has approved a ₹97.56 crore expansion plan

Aeroflex Industries Board has approved a ₹97.56 crore expansion plan

Published on 19-Dec-2025 09:01

As per media sources, HDFC Bank has raised a $1 billion three-year overseas loan from its GIFT City branch

As per media sources, HDFC Bank has raised a $1 billion three-year overseas loan from its GIFT City branch

Published on 19-Dec-2025 09:00

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

Published on 18-Dec-2025 09:07

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Published on 18-Dec-2025 09:06

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

Published on 18-Dec-2025 09:05

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status